Codexis (NASDAQ:CDXS) – First Analysis issued their Q3 2018 EPS estimates for Codexis in a report issued on Wednesday, April 4th. First Analysis analyst S. Schwartz anticipates that the biotechnology company will post earnings per share of ($0.02) for the quarter.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.03). Codexis had a negative net margin of 45.97% and a negative return on equity of 103.42%. The firm had revenue of $21.70 million for the quarter, compared to the consensus estimate of $22.97 million. During the same quarter last year, the company posted ($0.07) earnings per share. Codexis’s revenue for the quarter was up 117.0% compared to the same quarter last year.
Several other equities analysts have also issued reports on the company. BidaskClub upgraded Codexis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Thursday, February 15th. HC Wainwright set a $12.00 price target on Codexis and gave the stock a “buy” rating in a research report on Monday, March 12th. Finally, ValuEngine upgraded Codexis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $9.75.
CDXS opened at $10.40 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.76 and a current ratio of 1.80. Codexis has a 1 year low of $3.95 and a 1 year high of $13.60. The company has a market cap of $523.08, a P/E ratio of -20.80 and a beta of -1.73.
Several hedge funds have recently modified their holdings of CDXS. State Street Corp grew its position in shares of Codexis by 26.8% in the 2nd quarter. State Street Corp now owns 580,623 shares of the biotechnology company’s stock worth $3,168,000 after buying an additional 122,757 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Codexis by 30.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 35,264 shares of the biotechnology company’s stock worth $192,000 after buying an additional 8,244 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Codexis by 7.4% in the 2nd quarter. California State Teachers Retirement System now owns 72,298 shares of the biotechnology company’s stock worth $394,000 after buying an additional 5,000 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Codexis by 227.6% in the 3rd quarter. Wells Fargo & Company MN now owns 390,797 shares of the biotechnology company’s stock worth $2,599,000 after buying an additional 271,503 shares during the last quarter. Finally, Royce & Associates LP bought a new stake in shares of Codexis in the 3rd quarter worth approximately $1,089,000. Hedge funds and other institutional investors own 70.84% of the company’s stock.
In related news, Director Bernard J. Kelley sold 10,206 shares of the firm’s stock in a transaction that occurred on Wednesday, March 21st. The stock was sold at an average price of $12.22, for a total transaction of $124,717.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David V. Smith sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $10.37, for a total value of $62,220.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 105,337 shares of company stock worth $1,187,683. 9.80% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece of content was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/07/codexis-forecasted-to-post-q3-2018-earnings-of-0-02-per-share-cdxs.html.
Codexis Company Profile
Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.